2022-RA-858-ESGO Benefit of bevacizumab according to CA125 decline kinetic in first-line high grade serous ovarian carcinoma (HGSOC) patients in real-life setting

Autor:	Ondine Becker, Marion Chevrier, Laurence Gladieff, Florence Joly, Philippe Toussaint, Anne Floquet, Christophe Pomel, Helene Costaz, Maria Kfoury, Thibault de la Motte Rouge, Renaud Sabatier, Cecile Loaec, Eric Leblanc, Frederic Marchal, Pierre-Emmanuel Colombo, Emmanuel Barranger, Olivier Colomban, Lise Bosquet, Manuel Rodrigues, Benoit You
Rok vydání:	2022
Zdroj:	Ovarian cancer.
DOI:	10.1136/ijgc-2022-esgo.576
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::70b376de1a1984b318dc0ee30a2d2e54 https://doi.org/10.1136/ijgc-2022-esgo.576 Zobrazit plný text záznamu